Does the media favor RCUS or FDMT?

In the previous week, 4D Molecular Therapeutics had 4 more articles in the media than Arcus Biosciences. MarketBeat recorded 6 mentions for 4D Molecular Therapeutics and 2 mentions for Arcus Biosciences. 4D Molecular Therapeutics' average media sentiment score of 0.47 beat Arcus Biosciences' score of 0.35 indicating that 4D Molecular Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcus Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral 4D Molecular Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer FDMT or DYN?

In the previous week, Dyne Therapeutics had 9 more articles in the media than 4D Molecular Therapeutics. MarketBeat recorded 15 mentions for Dyne Therapeutics and 6 mentions for 4D Molecular Therapeutics. 4D Molecular Therapeutics' average media sentiment score of 0.47 beat Dyne Therapeutics' score of 0.15 indicating that 4D Molecular Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 4D Molecular Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Dyne Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer FDMT or ZLAB?

In the previous week, 4D Molecular Therapeutics had 1 more articles in the media than Zai Lab. MarketBeat recorded 6 mentions for 4D Molecular Therapeutics and 5 mentions for Zai Lab. 4D Molecular Therapeutics' average media sentiment score of 0.47 beat Zai Lab's score of -0.33 indicating that 4D Molecular Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 4D Molecular Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Zai Lab 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Do analysts recommend FDMT or GMTX?

4D Molecular Therapeutics currently has a consensus target price of $29.00, indicating a potential upside of 112.14%. Given 4D Molecular Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe 4D Molecular Therapeutics is more favorable than Gemini Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 4D Molecular Therapeutics 1 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.83 Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Does the media refer more to FDMT or PGEN?

In the previous week, Precigen had 8 more articles in the media than 4D Molecular Therapeutics. MarketBeat recorded 14 mentions for Precigen and 6 mentions for 4D Molecular Therapeutics. Precigen's average media sentiment score of 0.69 beat 4D Molecular Therapeutics' score of 0.47 indicating that Precigen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 4D Molecular Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Precigen 3 Very Positive mention(s) 5 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

4D Molecular Therapeutics (FDMT) Competitors

$13.67 -0.17 (-1.23%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$13.68 +0.01 (+0.07%)

As of 10/2/2026 07:30 PM Eastern

Compare

FDMT vs. RCUS, DYN, ZLAB, GMTX, and PGEN

Should you buy 4D Molecular Therapeutics stock or one of its competitors? 4D Molecular Therapeutics's main competitors and comparable companies include Arcus Biosciences (RCUS), Dyne Therapeutics (DYN), Zai Lab (ZLAB), Gemini Therapeutics (GMTX), and Precigen (PGEN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does 4D Molecular Therapeutics compare to Arcus Biosciences?

Arcus Biosciences (NYSE:RCUS) and 4D Molecular Therapeutics (NASDAQ:FDMT) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability, media sentiment and analyst recommendations.

4D Molecular Therapeutics has a net margin of -194.74% compared to Arcus Biosciences' net margin of -393.16%. 4D Molecular Therapeutics' return on equity of -41.33% beat Arcus Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcus Biosciences	-393.16%	-89.54%	-45.61%
4D Molecular Therapeutics	-194.74%	-41.33%	-35.90%

4D Molecular Therapeutics has lower revenue, but higher earnings than Arcus Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than 4D Molecular Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcus Biosciences	$247M	12.59	-$353M	-$3.90	N/A
4D Molecular Therapeutics	$85.21M	8.86	-$140.11M	-$2.63	N/A

Arcus Biosciences has a beta of 0.94, indicating that its share price is 6% less volatile than the broader market. Comparatively, 4D Molecular Therapeutics has a beta of 2.75, indicating that its share price is 175% more volatile than the broader market.

Arcus Biosciences currently has a consensus price target of $38.30, indicating a potential upside of 56.80%. 4D Molecular Therapeutics has a consensus price target of $29.00, indicating a potential upside of 112.14%. Given 4D Molecular Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe 4D Molecular Therapeutics is more favorable than Arcus Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.64
4D Molecular Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

In the previous week, 4D Molecular Therapeutics had 4 more articles in the media than Arcus Biosciences. MarketBeat recorded 6 mentions for 4D Molecular Therapeutics and 2 mentions for Arcus Biosciences. 4D Molecular Therapeutics' average media sentiment score of 0.47 beat Arcus Biosciences' score of 0.35 indicating that 4D Molecular Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcus Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
4D Molecular Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

92.9% of Arcus Biosciences shares are owned by institutional investors. Comparatively, 99.3% of 4D Molecular Therapeutics shares are owned by institutional investors. 7.6% of Arcus Biosciences shares are owned by company insiders. Comparatively, 7.9% of 4D Molecular Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

4D Molecular Therapeutics beats Arcus Biosciences on 14 of the 17 factors compared between the two stocks.

How does 4D Molecular Therapeutics compare to Dyne Therapeutics?

4D Molecular Therapeutics (NASDAQ:FDMT) and Dyne Therapeutics (NASDAQ:DYN) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, risk, earnings, analyst recommendations and media sentiment.

99.3% of 4D Molecular Therapeutics shares are held by institutional investors. Comparatively, 96.7% of Dyne Therapeutics shares are held by institutional investors. 7.9% of 4D Molecular Therapeutics shares are held by insiders. Comparatively, 9.5% of Dyne Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

4D Molecular Therapeutics has a beta of 2.75, meaning that its share price is 175% more volatile than the broader market. Comparatively, Dyne Therapeutics has a beta of 1.12, meaning that its share price is 12% more volatile than the broader market.

4D Molecular Therapeutics has higher revenue and earnings than Dyne Therapeutics. 4D Molecular Therapeutics is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
4D Molecular Therapeutics	$85.21M	8.86	-$140.11M	-$2.63	N/A
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.33	N/A

In the previous week, Dyne Therapeutics had 9 more articles in the media than 4D Molecular Therapeutics. MarketBeat recorded 15 mentions for Dyne Therapeutics and 6 mentions for 4D Molecular Therapeutics. 4D Molecular Therapeutics' average media sentiment score of 0.47 beat Dyne Therapeutics' score of 0.15 indicating that 4D Molecular Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
4D Molecular Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Dyne Therapeutics	2 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Dyne Therapeutics has a net margin of 0.00% compared to 4D Molecular Therapeutics' net margin of -194.74%. 4D Molecular Therapeutics' return on equity of -41.33% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
4D Molecular Therapeutics	-194.74%	-41.33%	-35.90%
Dyne Therapeutics	N/A	-64.30%	-50.33%

4D Molecular Therapeutics presently has a consensus price target of $29.00, indicating a potential upside of 112.14%. Dyne Therapeutics has a consensus price target of $33.07, indicating a potential upside of 117.58%. Given Dyne Therapeutics' higher probable upside, analysts clearly believe Dyne Therapeutics is more favorable than 4D Molecular Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
4D Molecular Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
Dyne Therapeutics	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.82

Summary

4D Molecular Therapeutics beats Dyne Therapeutics on 9 of the 16 factors compared between the two stocks.

How does 4D Molecular Therapeutics compare to Zai Lab?

4D Molecular Therapeutics (NASDAQ:FDMT) and Zai Lab (NASDAQ:ZLAB) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, earnings, analyst recommendations and dividends.

4D Molecular Therapeutics currently has a consensus price target of $29.00, indicating a potential upside of 112.14%. Zai Lab has a consensus price target of $37.25, indicating a potential upside of 53.10%. Given 4D Molecular Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe 4D Molecular Therapeutics is more favorable than Zai Lab.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
4D Molecular Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
Zai Lab	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

4D Molecular Therapeutics has higher earnings, but lower revenue than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than 4D Molecular Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
4D Molecular Therapeutics	$85.21M	8.86	-$140.11M	-$2.63	N/A
Zai Lab	$460.16M	6.02	-$175.54M	-$1.71	N/A

Zai Lab has a net margin of -41.86% compared to 4D Molecular Therapeutics' net margin of -194.74%. Zai Lab's return on equity of -27.43% beat 4D Molecular Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
4D Molecular Therapeutics	-194.74%	-41.33%	-35.90%
Zai Lab	-41.86%	-27.43%	-16.72%

99.3% of 4D Molecular Therapeutics shares are held by institutional investors. Comparatively, 41.7% of Zai Lab shares are held by institutional investors. 7.9% of 4D Molecular Therapeutics shares are held by company insiders. Comparatively, 4.9% of Zai Lab shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, 4D Molecular Therapeutics had 1 more articles in the media than Zai Lab. MarketBeat recorded 6 mentions for 4D Molecular Therapeutics and 5 mentions for Zai Lab. 4D Molecular Therapeutics' average media sentiment score of 0.47 beat Zai Lab's score of -0.33 indicating that 4D Molecular Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
4D Molecular Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zai Lab	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

4D Molecular Therapeutics has a beta of 2.75, meaning that its share price is 175% more volatile than the broader market. Comparatively, Zai Lab has a beta of 0.73, meaning that its share price is 27% less volatile than the broader market.

Summary

4D Molecular Therapeutics beats Zai Lab on 11 of the 16 factors compared between the two stocks.

How does 4D Molecular Therapeutics compare to Gemini Therapeutics?

4D Molecular Therapeutics (NASDAQ:FDMT) and Gemini Therapeutics (NASDAQ:GMTX) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, institutional ownership, risk and profitability.

Gemini Therapeutics has lower revenue, but higher earnings than 4D Molecular Therapeutics. Gemini Therapeutics is trading at a lower price-to-earnings ratio than 4D Molecular Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
4D Molecular Therapeutics	$85.21M	8.86	-$140.11M	-$2.63	N/A
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A

In the previous week, 4D Molecular Therapeutics had 6 more articles in the media than Gemini Therapeutics. MarketBeat recorded 6 mentions for 4D Molecular Therapeutics and 0 mentions for Gemini Therapeutics. 4D Molecular Therapeutics' average media sentiment score of 0.47 beat Gemini Therapeutics' score of 0.00 indicating that 4D Molecular Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
4D Molecular Therapeutics	Neutral
Gemini Therapeutics	Neutral

99.3% of 4D Molecular Therapeutics shares are owned by institutional investors. Comparatively, 75.4% of Gemini Therapeutics shares are owned by institutional investors. 7.9% of 4D Molecular Therapeutics shares are owned by insiders. Comparatively, 12.9% of Gemini Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

4D Molecular Therapeutics currently has a consensus target price of $29.00, indicating a potential upside of 112.14%. Given 4D Molecular Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe 4D Molecular Therapeutics is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
4D Molecular Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

4D Molecular Therapeutics has a beta of 2.75, indicating that its share price is 175% more volatile than the broader market. Comparatively, Gemini Therapeutics has a beta of -0.12, indicating that its share price is 112% less volatile than the broader market.

Gemini Therapeutics has a net margin of 0.00% compared to 4D Molecular Therapeutics' net margin of -194.74%. Gemini Therapeutics' return on equity of -38.78% beat 4D Molecular Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
4D Molecular Therapeutics	-194.74%	-41.33%	-35.90%
Gemini Therapeutics	N/A	-38.78%	-35.88%

Summary

4D Molecular Therapeutics beats Gemini Therapeutics on 10 of the 16 factors compared between the two stocks.

How does 4D Molecular Therapeutics compare to Precigen?

4D Molecular Therapeutics (NASDAQ:FDMT) and Precigen (NASDAQ:PGEN) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership, profitability and media sentiment.

99.3% of 4D Molecular Therapeutics shares are owned by institutional investors. Comparatively, 33.5% of Precigen shares are owned by institutional investors. 7.9% of 4D Molecular Therapeutics shares are owned by company insiders. Comparatively, 41.4% of Precigen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Precigen has a net margin of -183.98% compared to 4D Molecular Therapeutics' net margin of -194.74%. Precigen's return on equity of 423.75% beat 4D Molecular Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
4D Molecular Therapeutics	-194.74%	-41.33%	-35.90%
Precigen	-183.98%	423.75%	84.39%

4D Molecular Therapeutics presently has a consensus price target of $29.00, indicating a potential upside of 112.14%. Precigen has a consensus price target of $13.67, indicating a potential upside of 60.03%. Given 4D Molecular Therapeutics' higher possible upside, equities analysts plainly believe 4D Molecular Therapeutics is more favorable than Precigen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
4D Molecular Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
Precigen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

4D Molecular Therapeutics has a beta of 2.75, suggesting that its stock price is 175% more volatile than the broader market. Comparatively, Precigen has a beta of 0.92, suggesting that its stock price is 8% less volatile than the broader market.

4D Molecular Therapeutics has higher revenue and earnings than Precigen. Precigen is trading at a lower price-to-earnings ratio than 4D Molecular Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
4D Molecular Therapeutics	$85.21M	8.86	-$140.11M	-$2.63	N/A
Precigen	$9.68M	314.52	-$250.64M	-$1.04	N/A

In the previous week, Precigen had 8 more articles in the media than 4D Molecular Therapeutics. MarketBeat recorded 14 mentions for Precigen and 6 mentions for 4D Molecular Therapeutics. Precigen's average media sentiment score of 0.69 beat 4D Molecular Therapeutics' score of 0.47 indicating that Precigen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
4D Molecular Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Precigen	3 Very Positive mention(s)	5 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Precigen beats 4D Molecular Therapeutics on 8 of the 15 factors compared between the two stocks.

Get 4D Molecular Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FDMT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FDMT vs. The Competition

Export

Metric	4D Molecular Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$755.19M	$3.87B	$7.14B	$13.18B
Dividend Yield	N/A	3.64%	2.53%	16.78%
P/E Ratio	-5.20	13.06	275.68	26.04
Price / Sales	8.21	1,401.36	661.92	103.09
Price / Cash	N/A	122.60	77.60	51.75
Price / Book	1.54	16.63	10.93	6.31
Net Income	-$140.11M	-$22.71M	$3.51B	$362.16M
7 Day Performance	-5.53%	-2.99%	-2.00%	-1.66%
1 Month Performance	-7.01%	-10.60%	-6.15%	-4.50%
1 Year Performance	59.88%	19.44%	7.44%	2.06%

4D Molecular Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FDMT 4D Molecular Therapeutics	2.8468 of 5 stars	$13.67 -1.2%	$29.00 +112.1%	+57.7%	$755.19M	$92.01M	N/A	196	Analyst Forecast Gap Up
RCUS Arcus Biosciences	2.906 of 5 stars	$25.03 +0.2%	$38.30 +53.0%	+82.5%	$3.18B	$247M	N/A	601	Analyst Forecast
DYN Dyne Therapeutics	3.3327 of 5 stars	$16.34 +1.9%	$32.17 +96.9%	+21.1%	$2.99B	N/A	N/A	258	Analyst Forecast Analyst Revision
ZLAB Zai Lab	1.8426 of 5 stars	$25.69 +2.8%	$37.25 +45.0%	-28.1%	$2.84B	$460.16M	N/A	1,784
GMTX Gemini Therapeutics	N/A	$65.24 -1.8%	N/A	-5.1%	$2.83B	N/A	N/A	30	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FDMT) was last updated on 10/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

4D Molecular Therapeutics (FDMT) Competitors

FDMT vs. RCUS, DYN, ZLAB, GMTX, and PGEN

How does 4D Molecular Therapeutics compare to Arcus Biosciences?

Summary

How does 4D Molecular Therapeutics compare to Dyne Therapeutics?

Summary

How does 4D Molecular Therapeutics compare to Zai Lab?

Summary

How does 4D Molecular Therapeutics compare to Gemini Therapeutics?

Summary

How does 4D Molecular Therapeutics compare to Precigen?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FDMT vs. The Competition

4D Molecular Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

4D Molecular Therapeutics (FDMT) Competitors

FDMT vs. RCUS, DYN, ZLAB, GMTX, and PGEN

How does 4D Molecular Therapeutics compare to Arcus Biosciences?

Is RCUS or FDMT more profitable?

Which has preferable valuation and earnings, RCUS or FDMT?

Which has more risk and volatility, RCUS or FDMT?

Do analysts rate RCUS or FDMT?

Does the media favor RCUS or FDMT?

Do insiders and institutionals have more ownership in RCUS or FDMT?

Summary

How does 4D Molecular Therapeutics compare to Dyne Therapeutics?

Do institutionals and insiders believe in FDMT or DYN?

Which has more volatility & risk, FDMT or DYN?

Which has preferable valuation & earnings, FDMT or DYN?

Does the media prefer FDMT or DYN?

Is FDMT or DYN more profitable?

Do analysts recommend FDMT or DYN?

Summary

How does 4D Molecular Therapeutics compare to Zai Lab?

Do analysts recommend FDMT or ZLAB?

Which has stronger earnings and valuation, FDMT or ZLAB?

Is FDMT or ZLAB more profitable?

Do institutionals & insiders believe in FDMT or ZLAB?

Does the media prefer FDMT or ZLAB?

Which has more risk and volatility, FDMT or ZLAB?

Summary

How does 4D Molecular Therapeutics compare to Gemini Therapeutics?

Which has stronger earnings and valuation, FDMT or GMTX?

Does the media refer more to FDMT or GMTX?

Do institutionals and insiders believe in FDMT or GMTX?

Do analysts recommend FDMT or GMTX?

Which has more risk & volatility, FDMT or GMTX?

Is FDMT or GMTX more profitable?

Summary

How does 4D Molecular Therapeutics compare to Precigen?

Do insiders and institutionals believe in FDMT or PGEN?

Is FDMT or PGEN more profitable?

Do analysts recommend FDMT or PGEN?

Which has more volatility & risk, FDMT or PGEN?

Which has better valuation and earnings, FDMT or PGEN?

Does the media refer more to FDMT or PGEN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FDMT vs. The Competition

4D Molecular Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools